Narendranath Epperla

3.5k total citations
147 papers, 1.0k citations indexed

About

Narendranath Epperla is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Narendranath Epperla has authored 147 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 90 papers in Pathology and Forensic Medicine, 65 papers in Oncology and 46 papers in Genetics. Recurrent topics in Narendranath Epperla's work include Lymphoma Diagnosis and Treatment (89 papers), Chronic Lymphocytic Leukemia Research (39 papers) and CAR-T cell therapy research (31 papers). Narendranath Epperla is often cited by papers focused on Lymphoma Diagnosis and Treatment (89 papers), Chronic Lymphocytic Leukemia Research (39 papers) and CAR-T cell therapy research (31 papers). Narendranath Epperla collaborates with scholars based in United States, Egypt and Spain. Narendranath Epperla's co-authors include Mehdi Hamadani, Walter Hanel, Timothy S. Fenske, William G. Hocking, Fergus McKiernan, Apoorva Jayarangaiah, Lisa Baumann Kreuziger, Joseph J. Mazza, John L. Vaughn and Alex F. Herrera and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Narendranath Epperla

126 papers receiving 1.0k citations

Peers

Countries citing papers authored by Narendranath Epperla

Since Specialization

Citations

This map shows the geographic impact of Narendranath Epperla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Narendranath Epperla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Narendranath Epperla more than expected).

Fields of papers citing papers by Narendranath Epperla

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Narendranath Epperla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Narendranath Epperla. The network helps show where Narendranath Epperla may publish in the future.

Co-authorship network of co-authors of Narendranath Epperla

This figure shows the co-authorship network connecting the top 25 collaborators of Narendranath Epperla. A scholar is included among the top collaborators of Narendranath Epperla based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Narendranath Epperla. Narendranath Epperla is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Real-World Effectiveness of Tafasitamab (Tafa) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the United States 2024 ·Blood ·(unknown), Loretta J. Nastoupil, Bruce A. Feinberg, John P. Galvin, (unknown), (unknown), (unknown), (unknown), Narendranath Epperla	0
2	Cardiovascular toxicities associated with novel cellular immune therapies 2024 ·Blood Advances ·Malak Munir, Ahmed Sayed, Daniel Addison, Narendranath Epperla	2
3	Incidence, description, and timing of serious and opportunistic infections in patients with hairy cell leukemia 2024 ·SHILAP Revista de lepidopterología ·(unknown), Qiuhong Zhao, Andrew Stiff, Seema A. Bhat, Mirela Anghelina, Leslie A. Andritsos, James S. Blachly, Narendranath Epperla, Zeinab El Boghdadly, Michael R. Grever, Kerry A. Rogers	0
4	Secondary myeloid malignancy after CAR T cell therapy for non-Hodgkin lymphoma (NHL). 2024 ·Journal of Clinical Oncology ·(unknown), (unknown), (unknown), Pedro C. Silberman, (unknown), Yazeed Sawalha, Beth Christian, Kami J. Maddocks, Narendranath Epperla, Samantha Jaglowski, David A. Bond, Hannah Choe, Jonathan E. Brammer, Adam S. Kittai, Evandro D. Bezerra, Timothy Voorhees, Sumithira Vasu, Sarah Wall, (unknown), Nathan Denlinger	2
5	Transformation in marginal zone lymphoma: results from a prospective cohort and a meta-analysis of the literature 2024 ·Blood Advances ·(unknown), Brian K. Link, (unknown), Matthew J. Maurer, Melissa C. Larson, Arushi Khurana, Yucai Wang, Carrie A. Thompson, Dai Chihara, Juan Pablo Alderuccio, Jean L. Koff, Narendranath Epperla, Annarita Conconi, Izidore S. Lossos, Grzegorz S. Nowakowski, Andrew L. Feldman, Thomas M. Habermann, Rebecca L. King, James R. Cerhan	2
6	Siltuximab for chimeric antigen receptor T-cell therapy–related CRS and ICANS: a multicenter retrospective analysis 2024 ·Blood Advances ·(unknown), Qiuhong Zhao, (unknown), Chenyu Lin, (unknown), (unknown), Monalisa Ghosh, David Frame, Ahmed Galal, (unknown), Nausheen Ahmed, Evandro D. Bezerra, Nathan Denlinger, Marcos de Lima, Narendranath Epperla, Paolo F. Caimi, Timothy Voorhees	12
7	IMMUNOTHERAPY ALONE VERSUS CHEMOIMMUNOTHERAPY AS FIRST‐LINE TREATMENT OF MARGINAL ZONE LYMPHOMA (MZL): A REAL‐WORLD ANALYSIS 2023 ·Hematological Oncology ·Adam J. Olszewski, Narendranath Epperla, Dai Chihara, Thomas Ollila	1
8	Impact of Maintenance Rituximab Following First-Line Systemic Therapy on Outcomes in Patients with Marginal Zone Lymphoma: Real-World Evidence from 10 US Centers 2023 ·Blood ·Narendranath Epperla, (unknown), Geoffrey Shouse, Natalie S. Grover, Pallawi Torka, Marcus P. Watkins, (unknown), (unknown), (unknown), Montreh Tavakkoli, (unknown), Beth Christian, Colin Thomas, Stefan K. Barta, Praveen Ramakrishnan Geethakumari, Reem Karmali, Nancy L. Bartlett, Adam J. Olszewski	0
9	Zanubrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results from a Phase 1b Clinical Trial 2023 ·Blood ·Yazeed Sawalha, (unknown), (unknown), Brian Hess, Audrey M. Sigmund, Timothy Voorhees, Walter Hanel, David A. Bond, John Reneau, Narendranath Epperla, Lapo Alinari, Jonathan E. Brammer, Beth Christian, Robert A. Baiocchi, Kami J. Maddocks	0
10	A Multicenter Study Analyzing Survival and Prognostic Factors in Patients with Leukemic Phase Follicular Lymphoma 2023 ·Blood ·Asaad Trabolsi, Narendranath Epperla, (unknown), (unknown), (unknown), (unknown), (unknown), Lindsey Fitzgerald, Sunwoo Han, Isildinha M. Reis, Jennifer R. Chapman‐Fredricks, (unknown), Thomas Ollila, Reem Karmali, Izidore S. Lossos, Juan Pablo Alderuccio	1
11	Beyond Bruton’s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody–drug conjugates, CAR T-cells, and novel agents 2023 ·Journal of Hematology & Oncology ·Neeraj Jain, (unknown), Sayan Mullick Chowdhury, (unknown), (unknown), Lalit Sehgal, Narendranath Epperla	13
12	Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia 2020 ·Clinical Cancer Research ·Shanmugapriya Thangavadivel, Qiuhong Zhao, Narendranath Epperla, (unknown), Xiaokui Mo, Mohamed Badawi, (unknown), Mitch A. Phelps, Leslie A. Andritsos, Kerry A. Rogers, Jeffrey J. Jones, Jennifer A. Woyach, John C. Byrd, Farrukh T. Awan	3
13	Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT 2020 ·Blood Advances ·Talha Badar, Narendranath Epperla, Anikó Szabó, (unknown), John L. Vaughn, (unknown), Neeraj Saini, (unknown), Romil Patel, Sairah Ahmed, Nirav N. Shah, Amanda F. Cashen, Mehdi Hamadani, Timothy S. Fenske	13
14	Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation 2019 ·Blood Advances ·Narendranath Epperla, Talha Badar, Anikó Szabó, John L. Vaughn, (unknown), Neeraj Saini, Romil Patel, Nirav N. Shah, Mehdi Hamadani, Sairah Ahmed, Amanda F. Cashen, Timothy S. Fenske	20
15	Upfront autologous hematopoietic stem cell transplantation consolidation for patients with aggressive B‐cell lymphomas in first remission in the rituximab era: A systematic review and meta‐analysis 2019 ·Cancer ·Narendranath Epperla, Mehdi Hamadani, Tea Reljic, Mohamed A. Kharfan‐Dabaja, Bipin N. Savani, Ambuj Kumar	12
16	Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy 2018 ·Cancer ·Irl Brian Greenwell, Ashley D. Staton, Michael J. Lee, Jeffrey M. Switchenko, Debra Saxe, Joseph Maly, Kristie A. Blum, Natalie S. Grover, Stephanie Mathews, Max J. Gordon, Alexey V. Danilov, Narendranath Epperla, Timothy S. Fenske, Mehdi Hamadani, Steven I. Park, Christopher R. Flowers, Jonathon B. Cohen	34
17	Multicenter Analysis of Advanced Stage Grade 3A Follicular Lymphoma Outcomes by Frontline Treatment Regimen 2018 ·Clinical Lymphoma Myeloma & Leukemia ·Nirav N. Shah, Anikó Szabó, Raya Saba, Lauren E. Strelec, (unknown), John L. Vaughn, (unknown), David T. Yang, Anthony R. Mato, Abraham S. Kanate, Horatiu Olteanu, Mehdi Hamadani, Timothy S. Fenske, Vaishalee P. Kenkre, Jakub Svoboda, Amanda F. Cashen, Narendranath Epperla	9
18	Survival of Lymphoma Patients Experiencing Relapse or Progression after an Allogeneic Hematopoietic Cell Transplantation 2018 ·Biology of Blood and Marrow Transplantation ·Narendranath Epperla, Mehdi Hamadani, Kwang Woo Ahn, Fiona He, (unknown), (unknown), Parameswaran Hari, Marcelo C. Pasquini, Timothy S. Fenske, Michael Craig, Abraham S. Kanate, Veronika Bachanová	2
19	Effect of Routine Surveillance Imaging on the Outcomes of Patients With Classical Hodgkin Lymphoma After Autologous Hematopoietic Cell Transplantation 2017 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), Narendranath Epperla, Namrata Shah, (unknown), George Carrum, Parameswaran Hari, Sai Ravi Pingali, Mehdi Hamadani, Reem Karmali, Timothy S. Fenske	8
20	Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma 2017 ·Biology of Blood and Marrow Transplantation ·Narendranath Epperla, Kwang Woo Ahn, Philippe Armand, Samantha Jaglowski, Sairah Ahmed, Vaishalee P. Kenkre, Bipin N. Savani, Madan Jagasia, Nirav N. Shah, Timothy S. Fenske, Anna Sureda, Sonali M. Smith, Mehdi Hamadani	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact